【24h】

Interlaboratory study comparing the microbiological potency of spiramycins I, II and III.

机译:实验室间研究比较了螺旋霉素I,II和III的微生物效力。

获取原文
获取原文并翻译 | 示例
           

摘要

An interlaboratory study has been performed to determine the relative potencies of spiramycins (SPMs) I, II and III by diffusion or/and turbidimetric assays with Bacillus subtilis or Staphylococcus aureus as the test organisms. Six laboratories from three countries participated. Experimental procedures were according to the European Pharmacopoeia, 3rd ed. The activity of SPM I is markedly higher than that of SPM II and III. By diffusion, the activities of SPM II and III relative to SPM I were found to be 57 and 72%, respectively. The interlaboratory relative standard deviations (RSD) varied from 3.6 to 16.3%. By turbidimetry, the activities of SPM II and III relative to SPM I were found to be 45 and 52%, respectively. The interlaboratory RSD values varied from 2.6 to 7.7%. The results of the study were analyzed according to the ISO 5725-2 guidelines to determine the repeatability, the between-laboratory and the reproducibility variances of both methods.
机译:已经进行了一项实验室间研究,通过以枯草芽孢杆菌或金黄色葡萄球菌为受试生物的扩散或/和比浊测定法确定了螺旋霉素(SPM)I,II和III的相对效力。来自三个国家的六个实验室参加了会议。实验程序根据欧洲药典第3版。 SPM I的活性明显高于SPM II和III。通过扩散,发现相对于SPM I,SPM II和III的活性分别为57%和72%。实验室间相对标准偏差(RSD)从3.6%到16.3%不等。通过比浊法,发现SPM II和III相对于SPM I的活性分别为45%和52%。实验室间RSD值从2.6到7.7%不等。根据ISO 5725-2指南分析研究结果,以确定两种方法的重复性,实验室间和重现性差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号